161 related articles for article (PubMed ID: 7824198)
1. 6-Chloro-D,L-tryptophan, 4-chloro-3-hydroxyanthranilate and dexamethasone attenuate quinolinic acid accumulation in brain and blood following systemic immune activation.
Saito K; Markey SP; Heyes MP
Neurosci Lett; 1994 Sep; 178(2):211-5. PubMed ID: 7824198
[TBL] [Abstract][Full Text] [Related]
2. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
3. 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells).
Saito K; Chen CY; Masana M; Crowley JS; Markey SP; Heyes MP
Biochem J; 1993 Apr; 291 ( Pt 1)(Pt 1):11-4. PubMed ID: 8471029
[TBL] [Abstract][Full Text] [Related]
4. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia.
Saito K; Nowak TS; Markey SP; Heyes MP
J Neurochem; 1993 Jan; 60(1):180-92. PubMed ID: 8417138
[TBL] [Abstract][Full Text] [Related]
6. 4-chloro-3-hydroxyanthranilate attenuate quinolinic acid accumulation in brain following transient cerebral ischemia in the gerbil.
Saito K; Seishima M; Noma A; Suyama K; Markey SP; Heyes MP
Adv Exp Med Biol; 1996; 398():407-11. PubMed ID: 8906296
[No Abstract] [Full Text] [Related]
7. Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Naritsin DB; Saito K; Markey SP; Chen CY; Heyes MP
J Neurochem; 1995 Nov; 65(5):2217-26. PubMed ID: 7595510
[TBL] [Abstract][Full Text] [Related]
8. Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation.
Saito K; Nowak TS; Suyama K; Quearry BJ; Saito M; Crowley JS; Markey SP; Heyes MP
J Neurochem; 1993 Dec; 61(6):2061-70. PubMed ID: 8245962
[TBL] [Abstract][Full Text] [Related]
9. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation.
Saito K; Crowley JS; Markey SP; Heyes MP
J Biol Chem; 1993 Jul; 268(21):15496-503. PubMed ID: 8340378
[TBL] [Abstract][Full Text] [Related]
10. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.
Heyes MP; Chen CY; Major EO; Saito K
Biochem J; 1997 Sep; 326 ( Pt 2)(Pt 2):351-6. PubMed ID: 9291104
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency.
Saito K; Fujigaki S; Heyes MP; Shibata K; Takemura M; Fujii H; Wada H; Noma A; Seishima M
Am J Physiol Renal Physiol; 2000 Sep; 279(3):F565-72. PubMed ID: 10966936
[TBL] [Abstract][Full Text] [Related]
12. 3-Hydroxyanthranilic acid accumulation following administration of the 3-hydroxyanthranilic acid 3,4-dioxygenase inhibitor NCR-631.
Fornstedt-Wallin B; Lundström J; Fredriksson G; Schwarcz R; Luthman J
Eur J Pharmacol; 1999 Dec; 386(1):15-24. PubMed ID: 10611459
[TBL] [Abstract][Full Text] [Related]
13. Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice.
Saito K; Markey SP; Heyes MP
Brain Res; 1991 Apr; 546(1):151-4. PubMed ID: 1830237
[TBL] [Abstract][Full Text] [Related]
14. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
15. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase.
Chiarugi A; Moroni F
Neuropharmacology; 1999 Aug; 38(8):1225-33. PubMed ID: 10462134
[TBL] [Abstract][Full Text] [Related]
16. Quinolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD
Moffett JR; Arun P; Puthillathu N; Vengilote R; Ives JA; Badawy AA; Namboodiri AM
Front Immunol; 2020; 11():31. PubMed ID: 32153556
[TBL] [Abstract][Full Text] [Related]
17. 4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injury.
Yates JR; Heyes MP; Blight AR
J Neurotrauma; 2006 Jun; 23(6):866-81. PubMed ID: 16774472
[TBL] [Abstract][Full Text] [Related]
18. The kynurenine pathway and neurologic disease. Therapeutic strategies.
Heyes MP
Adv Exp Med Biol; 1996; 398():125-9. PubMed ID: 8906254
[TBL] [Abstract][Full Text] [Related]
19. 4-Chloro-3-hydroxyanthranilate inhibits quinolinate production in the rat hippocampus in vivo.
Walsh JL; Wu HQ; Ungerstedt U; Schwarcz R
Brain Res Bull; 1994; 33(5):513-6. PubMed ID: 8186995
[TBL] [Abstract][Full Text] [Related]
20. Quinolinic acid accumulation and functional deficits following experimental spinal cord injury.
Blight AR; Cohen TI; Saito K; Heyes MP
Brain; 1995 Jun; 118 ( Pt 3)():735-52. PubMed ID: 7600090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
